HIV-1 gag DNA

HIV-1 gag DNA refers to a class of experimental therapeutic and prophylactic vaccines that use plasmid-based delivery of the *gag* gene from human immunodeficiency virus type 1 (HIV-1). These vaccines are designed to induce cellular immune responses—primarily T cell responses—against highly conserved elements of the viral *gag* protein (notably the p24 region), which are less prone to mutation and critical for viral fitness. The mechanism involves intramuscular administration of a plasmid encoding either full-length or truncated/optimized versions of the *gag* gene; in some regimens, this is combined with cytokine adjuvants such as IL-12 or IL-15. The goal is to elicit robust CD4+ and CD8+ T cell immunity targeting regions essential for viral replication. Clinical studies have shown that these vaccines are generally well tolerated but have demonstrated only modest immunogenicity in humans so far. Developers include academic institutions and biotechnology companies such as Auro Vaccines (formerly Profectus BioSciences), Ichor Medical Systems, Wyeth AB (now part of Pfizer), and collaborations with research consortia[3][4][5][2][6].

Other names

HIV-1 Gag conserved element DNA vaccineHIV1 Gag conserved element DNA vaccineHIV 1 Gag conserved element DNA vaccineHIV-1 p24 gag conserved element DNA vaccineHIV1 p24 gag conserved element DNA vaccineHIV 1 p24 gag conserved element DNA vaccinefull-length p55 Gag DNA vaccine